Perrigo Wants Answers From Former Owner Of Its Branded Consumer Business
Perrigo reported a $804m impairment for its European branded OTC drug and nutritional products business for the July-September period and will file an arbitration claim against its former owners. Company also highlights Rx-to-OTC switch opportunities.
You may also be interested in...
A portfolio review concluded that 'the next step to unlock shareholder value is … exploring strategic alternatives for that Tysabri royalty stream,' CEO John Hendrickson said during Perrigo's third-quarter earnings briefing.
Galderma Labs' adapalene gel is pending launch as first OTC acne ingredient approved through an NDA and first new acne ingredient available OTC in 20 years, but company must play in a digitally-oriented marketplace.
Less than a month after moving up from president to CEO, John Hendrickson tells analysts during the firm's first-quarter earnings briefing that Perrigo's private label OTC drug business remains strong, with the next launch ready to ship, but growing European branded consumer product sales is more of a long-term goal.